Lead Product(s) : Alisertib,Anastrozole,Letrozole
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Puma Starts ALISCAâ„¢-Breast1 Trial for Alisertib in HR+, HER2- Breast Cancer
Details : MLN8237 (alisertib) is a high affinity, selective, orally bioavailable inhibitors of Aurora A. It is being developed for the treatment of HER2-negative, HR-positive metastatic breast cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 20, 2024
Lead Product(s) : Alisertib,Anastrozole,Letrozole
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 16, 2024
Lead Product(s) : Alisertib,Anastrozole
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Puma Biotechnology Allowed to Proceed Under IND for Alisertib in Metastatic Breast Cancer
Details : MLN8237 (alisertib) is a high affinity, selective, orally bioavailable inhibitors of Aurora A. It is being developed for the treatment of HER2-negative, HR-positive metastatic breast cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 20, 2024
Lead Product(s) : Alisertib,Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Puma Biotechnology Begin ALISCA-Lung1 Phase 2 Trial of Alisertib in Small Cell Lung Cancer
Details : MLN8237 (alisertib) is a high affinity, selective, orally bioavailable inhibitors of Aurora A. It is being developed for the treatment of small cell lung cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 13, 2024
Lead Product(s) : Alisertib,Anastrozole
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MLN8237 (alisertib) is a high affinity, selective, orally bioavailable inhibitors of Aurora A. It is being developed for the treatment of HER2-negative, HR-positive metastatic breast cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 12, 2023
Lead Product(s) : Alisertib,Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 23, 2023
Details : MLN8237 (alisertib), a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2023
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
Details : ALI-4201 (alisertib), a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2023
Lead Product(s) : Alisertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Puma Biotechnology
Deal Size : $294.3 million
Deal Type : Licensing Agreement
Details : Alisertib (MLN8237), is an adenosine triphosphate–competitive and reversible inhibitor of aurora kinase A and results in disruption of mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $7.0 million
September 20, 2022
Lead Product(s) : Alisertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Puma Biotechnology
Deal Size : $294.3 million
Deal Type : Licensing Agreement
Lead Product(s) : Alisertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 23, 2016
Lead Product(s) : Alisertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable